產(chǎn)品[
NCI-H1650 人非小細(xì)胞肺癌細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話(huà),可以
產(chǎn)品名稱(chēng):
NCI-H1650 人非小細(xì)胞肺癌細(xì)胞
產(chǎn)品型號(hào):
CRL-5883
產(chǎn)品廠(chǎng)商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
NCI-H1650 人非小細(xì)胞肺癌細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件!
NCI-H1650 人非小細(xì)胞肺癌細(xì)胞
的詳細(xì)介紹
NCI-H1650 人非小細(xì)胞肺癌細(xì)胞
|
|
CRL-5883?
|
|
$429.00
|
|
|
NCI-H1650 [H-1650, H1650]
|
|
|
AF Gazdar, JD Minna
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: lung
Tumor Stage: stage 3B
Disease: adenocarcinoma; bronchoalveolar carcinoma
Derived from metastatic site: pleural effusion
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
|
|
|
Isolation date: May, 1987
|
|
|
Amelogenin: X
CSF1PO: 11
D13S317: 11
D16S539: 11,12
D5S818: 11
D7S820: 8,9
THO1: 9.3
TPOX: 11
vWA: 18
|
|
|
EGFR (DelE746A750) [90471]
|
|
|
27 years
|
|
|
male
|
|
|
Caucasian, White
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Protocol:
-
Remove and discard culture medium.
-
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
-
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
-
Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: Complete growth medium supplemented with 5% DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
|
|
|
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
90471: Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455
|
|
|
